NeurAxis (NASDAQ:NRXS – Get Free Report) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its rivals? We will compare NeurAxis to similar businesses based on the strength of its valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.
Analyst Recommendations
This is a summary of current ratings and target prices for NeurAxis and its rivals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
NeurAxis Competitors | 241 | 760 | 2017 | 101 | 2.63 |
As a group, “Electromedical equipment” companies have a potential upside of 20.75%. Given NeurAxis’ rivals higher probable upside, analysts clearly believe NeurAxis has less favorable growth aspects than its rivals.
Profitability
Net Margins | Return on Equity | Return on Assets | |
NeurAxis | -633.10% | N/A | -926.02% |
NeurAxis Competitors | -76.82% | -44.69% | -2.31% |
Institutional & Insider Ownership
11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 46.1% of shares of all “Electromedical equipment” companies are owned by institutional investors. 14.6% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares NeurAxis and its rivals top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
NeurAxis | $2.46 million | -$14.63 million | -0.66 |
NeurAxis Competitors | $965.77 million | $82.54 million | -7.48 |
NeurAxis’ rivals have higher revenue and earnings than NeurAxis. NeurAxis is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
NeurAxis rivals beat NeurAxis on 8 of the 12 factors compared.
NeurAxis Company Profile
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.